THE RESEARCH OF DR. JACK ARBISER


  

The  Arbiser lab has made major strides in melanoma in 2015. Honokiol, a  small natural product from the Magnolia plant, was found to cause  mitochondrial normalization by the Arbiser lab and other labs. Most  melanomas contain Braf, and abnormal mitochondria are required for Braf  to transform melanoma. The Arbiser lab has developed and patented new  derivatives of honokiol. These derivatives normalize the mitochondria in  aggressive melanoma cells and inhibit the growth of melanoma cells  which are resistant to vemurafenib, the major drug used for melanoma.  This paper has been submitted to Oncotarget. In addition, Dr Arbiser has  collaborated with Dr Jing Chen to find


Read about recent studies by Dr. Jack Arbiser


  

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo Feburary 9th, 2016


Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling


PHIPing out: a genetic basis for tumor ulceration


Clinical Cancer Research September 14, 2008


Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78



Please make your donation today to continue this much needed research

image132

Born out of love. Found in hope.

image133

Post our link on your own Facebook page by clicking on the icon below. 
HELP SPREAD THE WORD!!!